肝脾CT比值在吡格列酮治疗非酒精性脂肪肝疗效评价中的应用

CT Value Ratio of Liver and Spleen for the Evaluation of the Therapeutic Effects of Nonalcohol- ic Fatty Liver Treated by Pioglitazone

【目的】应用CT肝／脾比值技术定量评价吡格列酮治疗非酒精性脂肪肝（NAFLD）的疗效。【方法】依中华医学会NAFLD诊断标准入选135例患者，进行常规体检、肝／脾CT扫描，服用吡格列酮3个月后，检测治疗前后血清生化指标、CT肝／脾比值及BMI的变化。【结果】经治疗后患者体重指数（BMI）无明显变化，丙氨酸氨基转移酶、甘油三酯等明显下降，与治疗前相比差异有显著性（P〈0．05），CT肝／脾比值治疗后较治疗前明显升高（P〈0．01）。【结论】吡格列酮可有效治疗NAFLD，肝CT平扫可准确定量肝内脂质水平。

[Objective] To investigate the application of computerized tomography（CT） value ratio of liver and spleen in the eva[uation of the therapeutic effects of pioglitazone for treating nonalcoholic fatty liver disease （NAFLD）. [Methods] A total of 135 patients were selected according to Chinese Medical Association＇s （CMA） standard of NAFLD. Physical examination was carried out and scanned by CT. Then patients were treated with pioglitazone for 3 months. All the above parameters were tested after treatment. [Results] After treatment, body mass index（BMI） had no obvious change, while serum alanine aminotransferase（ALT） and triglyeride（TG） decreased significantly. There was significant difference between before and after treatment （ P 〈0.05）. CT value ratio of liver and spleen after treatment was higher than that before treatment（ P〈 0.01）. [Conclusion] Pioglitazone can treat NAFLD effectively. The intrahepatic content of lipid can be measured precisely by CT.